Latest News & Features
Refine Search
article
 This webinar provides insights into the economics of intellectual property from one of the leading experts in the valuation of intangibles.   28 September 2021 
Patents
 The US Patent and Trademark Office has announced applicants can file for more prioritised examinations following an increase to the annual limit.   27 September 2021 
Patents
 Marvel has launched a slew of countersuits against a consortium of ex-Marvel writers and artists to win back copyrights to some of its most recognisable characters, including Spider-Man, Iron Man and Thor.   27 September 2021 
Patents
 Peugeot Motocycles has been fined for infringing a European patent owned by Italian scooter company Piaggio, after the automaker lost two lawsuits in France and Italy.   27 September 2021 
Patents
 Former wearable tech start-up Jawbone has filed two patent infringement suits against Google and Apple, claiming it is entitled to royalties for its noise-cancelling technology.   24 September 2021 
Copyright
 The Writers' Guild of Great Britain has published a new practice guide for crediting screenwriters working in British broadcasting, with the aim of standardising IP rights allotted by the “created by” credit.   24 September 2021 
Patents
 While the campaign to list DABUS as an inventor appeared to be waning, could a controversial opinion by Justice Birss herald a change of fortune?   24 September 2021 
Copyright
 A recently unsealed indictment has accused a prominent YouTuber and two associates of operating a $34 million cable TV piracy scheme.   23 September 2021 
Patents
 Plans are unfolding for new legislation to erode the power of the US Patent Trial and Appeal Board to reject inter partes reviews under the controversial NHK-Fintiv rule, Senator Patrick Leahy has announced.   23 September 2021 
Jurisdiction reports
 After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second Great Patent Cliff of 2019–2024. With it we find low-hanging fruit for generic/biosimilar market entrants, and the importance of having an elegant patent strategy enabling early market entry for generics and biosimilars is underscored.   23 September 2021 
Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.

